Orange Book product · Generic (ANDA)
BEXAROTENE
BEXAROTENE
At a glance
Apr 27, 2022
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 27, 2022
4 yr 2 mo ago
Today
Pharmaceutical detail
Active ingredient
BEXAROTENE
Strength
1%
Dosage form
GEL
Route
TOPICAL
TE code
AB
Application
ANDA 215398
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of BEXAROTENE
- 2000TARGRETINBrand (NDA)
NDA 021056 · BAUSCH
- 1999TARGRETINBrand (NDA)
NDA 021055 · BAUSCH
- 2024BEXAROTENEGeneric (ANDA)
ANDA 210352 · CIPLA
- 2024BEXAROTENEGeneric (ANDA)
ANDA 208628 · ASCENT PHARMS INC
- 2021BEXAROTENEGeneric (ANDA)
ANDA 209931 · TEVA PHARMS USA
- 2020BEXAROTENEGeneric (ANDA)
ANDA 203663 · HIKMA
- 2018BEXAROTENEGeneric (ANDA)
ANDA 210105 · AMNEAL PHARMS NY
- 2018BEXAROTENEGeneric (ANDA)
ANDA 209886 · UPSHER SMITH LABS
- 2018BEXAROTENEGeneric (ANDA)
ANDA 209861 · ANI PHARMS
- 2014BEXAROTENEGeneric (ANDA)
ANDA 203174 · BIONPHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
